Clinical analysis of the effect of systemic radionuclide therapy combined with the endocrine therapy for advanced prostate cancer, comparing with the only endocrine therapy

Purpose:To investigate the effect of the systemic radionuclide therapy for the pain of bone metastasis of advanced prostate cancer, comparing with the only endocrine therapy. Methods:From March 1998 to March 2001, 52 patients of advanced prostate cancer with bone metastasis accepted the treatment of bilateral orchidectomy and Flutaminde (250 mg every 8 hours) in this hospital. 15 of the 52 patients also accepted intravenously infusion of 89 Srcl 2 (148 MBq); 8 of the 52 patients accepted intravenously infusion of 153 Sm EDTMP (37MBq/kg once a month); the others accepted the only endocrine therapy.Results:14 of 15 patients who accepted 89 Srcl 2 infusion had obvious pain relief, and 6 patients in the 153 Sm EDTMP group had the same result. However, even changed the dose and type of the drugs, lessening of pain was observed in only 9 patients of the endocrine therapy group. By the way of the systemic bone screen of 99 Tcm MDP the bone metastasis lesions were controlled and recovered in 73% of the 89 Srcl 2 group, 62% of the 153 Sm EDTMP group and 24% of the only endocrine therapy group. The leukothrombopenia was observed in 3 patients of the 89 Srcl 2 group and 2 patients of the 153 Sm EDTMP group. Then all of them had recovered after the expectant treatment.Conclusions:The systemic radionuclide therapy can obviously relief the pain caused by the bone metastasis of advanced prostate cancer and inhibit the development of bone metastasis lesions effectively. But during the treatment the blood cell counts shall be followed up carefully.